Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | RXRA | P19793 | 1/20 | 0.61 |
| ▸ | MPC2 | O95563 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12045490 | 0.91 | PPARG (0.58) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL12074888 | 0.91 | PPARG (0.67) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL12045501 | 0.90 | PPARG (0.66) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL12045504 | 0.89 | PPARG (0.60) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL12045493 | 0.89 | PPARG (0.64) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL12045508 | 0.88 | PPARG (0.63) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL12045506 | 0.88 | PPARG (0.63) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL12045510 | 0.88 | PPARG (0.58) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL12045494 | 0.87 | PPARG (0.62) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL19115182 | 0.87 | PPARG (0.62) | PPARGCYP3A4RXRAMPC2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196848-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | ALKERMES PHARMA IRELAND LTD (IE) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196848-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | PHPT1, SI, CA6 | PPARG 3793/4885CYP3A4 765/4885RXRA 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.